Oxcarbazepine Structural Formula (Oxcarbazepine 01)
Oxcarbazepine Suspension
Product Images NDC 42806-600
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 42806-600). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Epic Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Oxcarbazepine 02)
The log-rank test analysis shows a p-value of 0.0001 for the Oxcarbazepine treatment group. The rest of the text appears to be a combination of numerical values and column/axis labels, but it is not available to determine their significance without additional context.*
Figure 2: Kaplan-meier Estimates Of First Seizure Event Rate By Treatment Group (Oxcarbazepine 03)
This appears to be a graph showing the number of days from the first dose of a treatment (Oxcarbazeping or Placebo) to the first seizure. It seems to display time on the x-axis and number of days on the y-axis, and includes numbered and labeled ticks on both axes. There are also various numbered values plotted along the y-axis, likely indicating the number of days between doses or some other relevant time interval. The graph includes a key indicating which treatment group each color represents.*
Figure 3 Kaplan-meier Estimates Of Exit Rate By Treatment Group (Oxcarbazepine 04)
The given text presents the results of a log-rank test with a p-value of 0.0001. The remaining text appears to be a graph with a horizontal axis showing the range of days for "Time to exit" and a treatment group represented by HIGH and LOW. However, the graph is not properly formatted and may not be useful for interpretation.*
Figure 4 Kaplan-meier Estimates Of Exit Rate By Treatment Group (Oxcarbazepine 05)
Cap (Oxcarbazepine 06)
Bottle (Oxcarbazepine 07)
Filler (Oxcarbazepine 08)
Shake (Oxcarbazepine 09)
Insert (Oxcarbazepine 10)
Mix (Oxcarbazepine 11)
Inject (Oxcarbazepine 12)
Extract1 (Oxcarbazepine 13)
Extract1 (Oxcarbazepine 14)
Revolve (Oxcarbazepine 15)
Dispense (Oxcarbazepine 17)
Principal Display Panel-300 mg/5 mL (Oxcarbazepine 18)
Each 5 mL of the medicine contains 300 mg of oxcarbazepine, USP. The recommended dosage can be found in the package insert. The medicine should be stored in the original container at a temperature of 20° to 25°C (68° to 77°F); excursions up to 15° to 30°C (55°F to 86°F) are permitted. It should be used within 7 weeks of first opening the bottle and kept out of the reach of children. The medication should be shaken well before use. The medication guide should be dispensed to the patient by the pharmacist. This medicine is distributed by Epic Pharma, LLC in Lauretion, NY, and made in Canada. The NDC number is 42806-600-22.*
Principal Display Panel (300 mg/5 mL carton)
This is a medication label for Oxcarbazepine Oral Suspension, USP in the strength of 300mg/5mL. It is important to shake the bottle well before using, and the pharmacist should dispense medication guide provided separately to each patient. The medication should be stored in its original container and kept out of the reach of children. The NDC number for this product is 42806-600-22. The dosage information is available on the package, and the medication should be used within 7 weeks of opening.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
